Market Scan & Assessment of U.S. Centers for Heart Failure Gene Therapy
Situation
Our client was looking to assess treatment centers in the US to identify the most relevant hospitals for delivering novel gene therapies that are indicated for Heart Failure.
Objective
The goal was to better understand the treatment centers readiness, capacity, and timelines for onboarding a new heart failure gene therapy.
Our Work
10EQS supported the Client with conducting double-blinded interviews with a cross-section of stakeholders, including Heart Failure Specialists, Interventional Cardiologists, and Surgeons to assess clinical readiness, infrastructure, and onboarding feasibility. Experts were rigorously screened for relevant specialty, experience, and involvement in advanced heart failure treatment and related procedures.
Project team
- 10EQS Delivery Operations (=PMO) providing quality assurance, process management and expert recruitment
- 8 industry experts
Industry experts (excerpt)
- Board Member, Cardiovascular Innovation – Large Renowned Academic Medication Center
- Advanced Heart Failure and Transplant Cardiologist – Mid-sized Academic Hospital
- Interventional Cardiologist – Small Medical Center
- Associate Program Director Advanced Heart Failure – Large, Renowned Academic Medication Center
- Clinical Pharmacist Specialist, Cardiology – Mid-sized Medical Center
- Advanced Heart Failure Nurse Practitioner – Mid-sized Medical Center
Results
10EQS determined treatment centers demonstrating strong clinical alignment and operational preparedness, along with detailed insights on activation timelines, staffing, and infrastructure capabilities. The findings enabled the client to prioritize strategic sites for partnership and inform their potential launch strategy.